Identification of Novel Helper Epitopes of MAGE-A4 Tumour Antigen: Useful Tool for the Propagation of Th1 Cells

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Mar 12

PMID 19277034

Citations 6

Authors

T Ohkuri

D Wakita

K Chamoto

Y Togashi

H Kitamura

T Nishimura

Affiliations

Soon will be listed here.

Abstract

MAGE-A4 has been considered as an attractive cancer-testis (CT) antigen for tumour immunotherapy. It has been well accepted that T-helper type 1 (Th1) cell-dominant immunity is critical for the successful induction of antitumour immunity in a tumour-bearing host. The adoptive Th1 cell therapy has been shown to be an attractive strategy for inducing tumour eradication in mouse systems. However, Th1-cell therapy using human tumour-specific Th1 cells, which were expanded from peripheral blood mononuclear cells (PBMCs) in a clinically useful protocol, has never been performed. Here, we first identified MAGE-A4-derived promiscuous helper epitope, peptide (MAGE-A4 280-299), bound to both HLA-DPB1(*)0501 and DRB1(*)1403. Using the peptide, we established a suitable protocol for the propagation of MAGE-A4-specific Th1 cells in vitro. Culture of CD4(+) T cells with IFN-gamma-treated PBMC-derived adherent cells in the presence of helper epitope peptide resulted in a great expansion of MAGE-A4-reactive Th cells producing IFN-gamma , but not IL-4. Moreover, it was shown that ligation of MAGE-A4-reactive Th1 cells with the cognate peptide caused the production of IFN-gamma and IL-2. Thus, our identified MAGE-A4 helper epitope peptide will become a good tool for the propagation of tumour-specific Th1 cells applicable to adoptive immunotherapy of human cancer.

Citing Articles

SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity.

Yajima Y, Kosaka A, Ohkuri T, Hirohashi Y, Li D, Nagasaki T Heliyon. 2023; 9(9):e20192.

PMID: 37809871 PMC: 10559948. DOI: 10.1016/j.heliyon.2023.e20192.

A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity.

Yajima Y, Kosaka A, Ishibashi K, Yasuda S, Komatsuda H, Nagato T Cancer Sci. 2022; 113(8):2526-2535.

PMID: 35579200 PMC: 9357613. DOI: 10.1111/cas.15429.

A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy.

Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N Cancer Sci. 2021; 112(7):2705-2713.

PMID: 34009705 PMC: 8253266. DOI: 10.1111/cas.14973.

Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.

Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H Cancer Sci. 2017; 108(10):1947-1952.

PMID: 28749573 PMC: 5623748. DOI: 10.1111/cas.13332.

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.

Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y Cancer Sci. 2012; 103(1):150-3.

PMID: 22221328 PMC: 11164142. DOI: 10.1111/j.1349-7006.2011.02106.x.

References

Vignard V, Lemercier B, Lim A, Pandolfino M, Guilloux Y, Khammari A . Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol. 2005; 175(7):4797-805. DOI: 10.4049/jimmunol.175.7.4797. View

Sato M, Iwakabe K, Kimura S, Nishimura T . Functional skewing of bone marrow-derived dendritic cells by Th1- or Th2-inducing cytokines. Immunol Lett. 1999; 67(1):63-8. DOI: 10.1016/s0165-2478(98)00186-2. View

Sun J, Williams M, Bevan M . CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004; 5(9):927-33. PMC: 2776074. DOI: 10.1038/ni1105. View

Lu Z, Yuan L, Zhou X, Sotomayor E, Levitsky H, Pardoll D . CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med. 2000; 191(3):541-50. PMC: 2195823. DOI: 10.1084/jem.191.3.541. View

Smith C, Wilson N, Waithman J, Villadangos J, Carbone F, Heath W . Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol. 2004; 5(11):1143-8. DOI: 10.1038/ni1129. View

De Plaen E, Arden K, Traversari C, Gaforio J, Szikora J, De Smet C . Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994; 40(5):360-9. DOI: 10.1007/BF01246677. View

Giuntoli 2nd R, Lu J, Kobayashi H, Kennedy R, Celis E . Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res. 2002; 8(3):922-31. View

Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P . A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens. 2002; 60(5):365-71. DOI: 10.1034/j.1399-0039.2002.600503.x. View

Chamoto K, Tsuji T, Funamoto H, Kosaka A, Matsuzaki J, Sato T . Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 2004; 64(1):386-90. DOI: 10.1158/0008-5472.can-03-2596. View

10.

Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H . An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 2006; 66(3):1809-17. DOI: 10.1158/0008-5472.CAN-05-2246. View

11.

Schoenberger S, Toes R, van der Voort E, Offringa R, Melief C . T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998; 393(6684):480-3. DOI: 10.1038/31002. View

12.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

13.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

14.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

15.

Zhang Y, Wakita D, Chamoto K, Narita Y, Matsubara N, Kitamura H . Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol. 2006; 19(2):151-61. DOI: 10.1093/intimm/dxl132. View

16.

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

17.

Lin J, Lin L, Thomas D, Greenson J, Giordano T, Robinson G . Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res. 2004; 10(17):5708-16. DOI: 10.1158/1078-0432.CCR-04-0468. View

18.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T . The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004; 95(9):697-703. PMC: 11159994. DOI: 10.1111/j.1349-7006.2004.tb03248.x. View

19.

Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D . Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006; 28(5):1089-98. View

20.

Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M . Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 2004; 64(4):1490-5. DOI: 10.1158/0008-5472.can-03-2780. View